CelLBxHealth PLC (FRA:DWV) Stock Price, Trades & News

CelLBxHealth PLC is engaged in the development and commercialisation of the Parsortix platform, with deployment in liquid biopsy - non-invasive cancer diagnostics. It operates in single segment of commercialisation of its Parsortix cell separation platform. It generates revenue from contracts with customers in the research-use market, with customers located across multiple geographic regions. Geographically it operates in UK, Europe, North America, and Rest of World with majority of revenue deriving from Europe and North America.

Financial Strength

Name	Current	Vs Industry
Cash-To-Debt	2.19
Equity-to-Asset	0.53
Debt-to-Equity	0.32
Debt-to-EBITDA	-0.2
Piotroski F-Score	2/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	-19.6	Distress Grey Safe
Beneish M-Score	-8.36	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

	Name	Current	Vs Industry		Vs History
	3-Year EBITDA Growth Rate	23.8
	3-Year EPS without NRI Growth Rate	13.1
	3-Year FCF Growth Rate	28.2
	3-Year Book Growth Rate	-66
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	71.89
	Future 3-5Y Total Revenue Growth Rate Estimate	90.16

Momentum Rank

	Name	Current	Vs Industry		Vs History
	5-Day RSI	36.2
	9-Day RSI	34.35
	14-Day RSI	38.25
	3-1 Month Momentum %	70
	6-1 Month Momentum %	25.93
	12-1 Month Momentum %	-74.44

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.54
	Quick Ratio	2.07
	Cash Ratio	1.18
	Days Inventory	1155.83
	Days Sales Outstanding	418.12
	Days Payable	1182.36

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-63.3
	Shareholder Yield %	17.64

Profitability Rank

	Name	Current	Vs Industry		Vs History
	Gross Margin %	63.37
	Operating Margin %	-727.08
	Net Margin %	-1123.44
	EBITDA Margin %	-582.55
	FCF Margin %	-765.96
	OCF Margin %	-751.7
	ROE %	-168.81
	ROA %	-100.91
	ROIC %	-133.51
	3-Year ROIIC %	-71.11
	ROC (Joel Greenblatt) %	-294.84
	ROCE %	-125.33
	Moat Score	4
	Tariff Resilience Score	6

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	PS Ratio	4.25
	PB Ratio	3.19
	EV-to-EBIT	-1.06
	EV-to-Forward-EBIT	-2.15
	EV-to-EBITDA	-1.93
	EV-to-Forward-EBITDA	-2.53
	EV-to-Revenue	11.18
	EV-to-Forward-Revenue	6.15
	EV-to-FCF	-1.46
	Price-to-GF-Value	0.36
	Price-to-Median-PS-Value	0.04
	Earnings Yield (Greenblatt) %	-94.61
	FCF Yield %	-61.1

Financials (Next Earnings Date:2026-09-09 Est.)

Annual Quarterly TTM

FRA:DWV's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

CelLBxHealth PLC Executives

Details

GF Value™: €0.04

FRA:DWV

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 4 Severe warning signs with DWV. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	1.325
	EPS (TTM) (€)	-0.04
	Beta	41.1355
	3-Year Sharpe Ratio	0.74
	3-Year Sortino Ratio	11.58
	Volatility %	2796.8
	14-Day RSI	38.25
	14-Day ATR (€)	0.000526
	20-Day SMA (€)	0.0155
	12-1 Month Momentum %	-74.44
	52-Week Range (€)	0.0005 - 0.113
	Shares Outstanding (Mil)	1,136.4

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	2
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

CelLBxHealth PLC Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

CelLBxHealth PLC Stock Events

Financials Calendars

Event	Date	Price (€)
Second quarter earnings results for 2026	2026-07-15	0.02 (+0.00%)
General meeting for 2025	2026-07-14 08:00	0.02 (+0.00%)
Fourth quarter earnings conference call for 2025	2026-06-22 10:00	0.02 (+0.00%)
Fourth quarter earnings results for 2025	2026-06-22	0.02 (+0.00%)
Annual report for 2025	2026-06-19	0.02 (-2.50%)
Analyst meeting for 2025	2025-11-26 14:00	0.01 (+0.00%)
Second quarter earnings conference call for 2025	2025-09-09 10:00	0.06 (-14.77%)
Second quarter earnings results for 2025	2025-09-09	0.06 (-14.77%)
General meeting for 2024	2025-06-30 14:00	0.09 (+7.14%)
Annual report for 2024	2025-06-06	0.09 (+0.00%)

Show

Entries

CelLBxHealth PLC Frequently Asked Questions

What is CelLBxHealth PLC(FRA:DWV)'s stock price today?

The current price of FRA:DWV is €0.01. The 52 week high of FRA:DWV is €0.11 and 52 week low is €0.00.

When is next earnings date of CelLBxHealth PLC(FRA:DWV)?

The next earnings date of CelLBxHealth PLC(FRA:DWV) is 2026-09-09 Est..

Does CelLBxHealth PLC(FRA:DWV) pay dividends? If so, how much?

CelLBxHealth PLC(FRA:DWV) does not pay dividend.

Press Release

	Subject	Date
	Angle PLC Announces Harvesting CTCs from Brain Metastasis Patients	2021-07-09
	Angle PLC Announces Exercise of Options and Total Voting Rights	2021-04-30
	Angle PLC Announces Parsortix-Harvested CTCs Uncover Novel Biomarker	2021-02-18
	Angle PLC Announces Holding(s) in Company - (1)	2020-07-08
	Angle PLC Announces Holding(s) in Company - (2)	2020-07-08
	Angle PLC Announces AACR 2019	2019-04-11

10/Page

Articles on CelLBxHealth PLC

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.